"Potential to become a juggernaut"-absolutely B
Post# of 72440
BOM is phase 3 ready and a good foundation but the interest in IBD is a gigantic step in potential valuation of any deal. ABSSSI and Kevetrin? Wouldn't know how to even begin to value that.
"the road is not short"-no way for anyone to know that
If anyone believes that they themselves know the "potential" of the company then you really should believe that any interested pharmaceutical company (whose people do this for a living) is starting to realize it as well if they haven't known for a while now. If more than one is interested, who knows?
Congratulations to all who are in, and I hope those considering don't get left behind.